We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
e-therapeutics
Second agreement helps validate capabilitiesHutchison China MediTech
Carrying momentum into H219Bonesupport
All eyes on Q3 following a record Q2MaxCyte
Ideally placed to sustain growthMereo BioPharma
Accelerated approval path for NAVIScancell
Ground prepared for an important periodHutchison China MediTech
Secondary ADS offering trims CK Hutchison stakeBerGenBio
Private placement to support randomised Phase II trialsHutchison China MediTech
Surufatinib on track for potential 2020 China approvalHutchison China MediTech
Impressive data means SANET-ep trial stopped early